About Us

Bill Gerhart has more than 20 years of experience building high-performance execution teams to develop new therapeutics for serious diseases. Prior to joining Kinevant in 2021, he was the CEO of Respivant/Patara Pharma, Elevation Pharma, and Mpex Pharma which focused on developing new medicines for pulmonary fibrosis, chronic obstructive pulmonary disease, and cystic fibrosis, respectively. In addition to his biotech activities, Bill serves as the Chair of Sanford Burnham Prebys Institute’s Board of Trustees, a non-profit medical research institute focused on basic and translational research in cancer, neurodegeneration, infectious, and inflammatory diseases.

Bill earned a BA from Baylor University and an MBA from Harvard Business School.

Tuan Nguyen has more than 15 years of experience in biopharma working on small molecules and AAV gene therapies. Most recently, he was VP of Finance at Adverum Biotechnologies. Prior to that he held various senior Finance leadership roles at Intarcia Therapeutics, Fibrogen, and UCB. He has helped raise over $1 billion in dilutive and non dilutive capital. Tuan earned his MBA with dual concentration in Finance and Entrepreneurship, Innovation, & Change from Emory University.

Jill has more than 25 years of experience in clinical research at CRO, biopharma, and large pharma companies. Prior to Kinevant, Jill was most recently VP of Clinical Development at Enzyvant (Sumitovant/Altavant), where she led clinical research and operations. Prior to Enzyvant, Jill held various clinical research roles at Arbutus, Gilead, Pharmasset, and GSK. Jill was part of the team that brought the cure for Hepatitis C (Sovaldi and Harvoni) from first in human clinical studies to the market. Jill spent 10 years of her career in clinical pharmacology, beginning as Director of a Clinical Pharmacology Unit, and after, leading later-stage complex clinical programs.

Jill earned her MA in exercise physiology at the University of North Carolina at Chapel Hill.

Tim Noffke has more than 25 years of experience in the biopharma industry leading the global cross-functional development of biologics, biosimilars, new chemical entities, and small molecule generics across a variety of therapeutic areas. Prior to joining Kinevant, Tim was most recently Vice President, Program Management and Chief of Staff at Aptinyx, a clinical-stage biotech focused on novel therapies for neurological diseases. Before Aptinyx, Tim served in cross-functional leadership roles in R&D and Operations at Pfizer and Hospira advancing portfolio, program, and partnering priorities.

Tim earned a BS in chemical engineering from Northwestern University.

Cynthia Scott has more than 15 years of regulatory experience working on biologics and small molecules, in the areas of diabetes, oncology, infectious diseases, and rare diseases. Prior to joining Kinevant, Cynthia served as a regulatory consultant for over 10 years where she led cross-functional teams toward global product development goals, providing regulatory strategy and team leadership, ranging from early to late phase development.

Cynthia earned a BS from Eastern Nazarene College and an MS in Drug Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Health Sciences.

Frances Seput Dingle has more than 25 years of experience in clinical data management. Before Kinevant, she was most recently a Senior Director of Clinical Data Management at Exelixis, leading the data management team for its Phase I-III oncology studies. Prior to Exelixis, Frances held various positions in the clinical data management function at CymaBay Therapeutics, Clovis Oncology, BioMarin Pharmaceutical, Genentech and Hoffmann La Roche.

Frances earned a BS in Chemistry, Food, and Nutrition from Rutgers University-Douglass College.

Hajira has more than 15 years of experience across clinical development, medical affairs, scientific communications and publishing. Prior to joining Kinevant, Hajira was Senior Director Clinical Scientist at BioXcel Therapeutics. Before this, she served as Clinical Director at Praxis Precision Medicines and Takeda supporting early and late phase programs in psychiatry (agitation in Alzheimer’s disease, dementia, bipolar disorder and schizophrenia), neurology (essential tremor and Parkinson’s disease) and rare diseases (alpha-1 antitrypsin deficiency and ANCA-associated vasculitis).

Hajira earned a PhD in Neurosciences from Weill Cornell Graduate School of Medical Sciences and a BSc in Biochemistry from Worcester Polytechnic Institute.

Rayne has over eleven years of experience in patient advocacy, clinical trial recruitment, data science innovation, and program management.  Prior to Kinevant, Rayne worked with the Muscular Dystrophy Association as the Vice President of MOVR – a unified, national patient data hub for neuromuscular diseases – facilitating research initiatives with pharmaceutical and academic partners.  Before MDA, Rayne led global patient recruitment and advocacy efforts at miRagen Therapeutics across multiple rare hematological malignancies as the Director of Medical and Patient Affairs.  Rayne was also a Program Manager at Takeda where she launched a novel, systematic study of exceptional drug responders to oncology treatments, in collaboration with Harvard Medical School.

Rayne earned a BS in Finance from the University of Florida and an MPH from Emory University.

Laura Hathaway has close to 20 years of experience in the accounting field. After starting her career in public accounting at Deloitte for 5 years, Laura held roles of increasing responsibility in the retail and biotech industries. Laura is a licensed CPA and earned a BS in Business Administration from UC Berkeley.